Audio: HBV at AASLD 2023
New Audio Updates: CCO Independent Conference Coverage of Hepatitis B at AASLD 2023

Released: November 30, 2023

Nancy Reau
Nancy Reau, MD

Activity

Progress
1
Course Completed

In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:

  • Current therapies

    • Studies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDF
    • Kaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis B
    • Early vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV Transmission
  • Investigational functional cure strategies
     
    • B-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV Infection
    • MARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV Infection
    • REEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHB
    • HBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV Infection
    • CVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV Infection